Background. Diabetic nephropathy is a leading cause of end-stage renal disease. Premature mortality is common in patients with nephropathy, largely due to cardiovascular disease. Genetic variants implicated in macrovascular disease are therefore excellent candidates to assess for association with diabetic nephropathy. Recent genome-wide association studies have identified a total of 15 single-nucleotide polymorphisms (SNPs) that are reproducibly associated with cardiovascular disease. Methods. We initially assessed these SNPs for association in UK type 1 diabetic patients with (cases; n = 597) and without (controls; n = 502) nephropathy using iPLEX TM and TaqMan R assays. Replication studies were performed with DNA genotyped in a total of 2668 individuals from the British Isles. Results. One SNP (rs4420638) on chromosome 19q13 was found to be significantly associated with diabetic nephropathy before (P = 0.0002) and after correction for multiple testing (P corrected = 0.002). We replicated this finding in a phenotypically similar case-control collection comprising 709 individuals with type 1 diabetes (P = 0.002; combined P < 0.00001; OR = 1.54, 95% CI: 1.29-1.84). Conclusions. Our case-control data suggest that rs4420638, or a functional SNP in linkage disequilibrium with this SNP, may be associated with diabetic nephropathy.
Introduction
Diabetic nephropathy is now the leading cause of end-stage renal disease in developed countries [1] , and is associated with a 10-fold increased risk of macrovascular events [2] . Family studies have also shown that parents of individuals with diabetic nephropathy are more susceptible to hypertension, cardiovascular and cerebrovascular disease with associated premature mortality [3, 4] . Aggressive management of hyperglycaemia, hypertension and cardiovascular risk factors in individuals with diabetic nephropathy has been recommended by the UK National Service Frameworks for diabetes and renal services [5] .
Diabetic nephropathy exhibits a multifactorial aetiology, but determining definitive genetic risk factors has proved challenging [6, 7] . Several recent large-scale association studies [8] [9] [10] have identified 15 single-nucleotide polymorphisms (SNPs) that demonstrated strong prior evidence of association or were robustly replicated loci associated with an increased risk of cardiovascular disease. We have assessed these SNPs for association with diabetic nephropathy in white individuals recruited as part of multicentre collections in the British Isles.
Subjects and methods
Approval to conduct this study was obtained from the appropriate Research Ethics Committees, and all those recruited provided written informed consent. We obtained a total of 1099 genomic DNA samples from white, unrelated individuals with type 1 diabetes diagnosed before 31 years of age and who were insulin dependent from diagnosis. This population includes individuals recruited as part of the UK Warren 3/Genetics of Kidneys in Diabetes (GoKinD) collection [11] . Cases (n = 597) had onset of persistent proteinuria (>0.5 g/24 h) at least 10 years after diagnosis of diabetes with evidence of hypertension (>135/85 mmHg or treatment with antihypertensive medication) and retinopathy. Controls (n = 502) had diabetes for more than 15 years, with no evidence of renal disease and were not prescribed antihypertensive medication.
Genomic DNA was also available from 709 white individuals of Irish descent (parents and grandparents born in the island of Ireland) [12] . Cases (n = 267) and controls (n = 442) were recruited with the same inclusion/exclusion criteria as the UK population except that these individuals had type 1 diabetes diagnosed before 35 years of age. Similar clinical characteristics were observed for both groups (Table 1) . Genomic DNA was also available on 122 parent-affected offspring trios derived from the UK Warren 3 collection; affected offspring were recruited according to the same criteria as described above for UK cases (http://www.diabetes.org.uk/en/About_us/News_Landing_Page/2865). To minimize population heterogeneity, all recruited individuals were at least second generation born in the British Isles, with similar phenotypic inclusion criteria. Individuals with microalbuminuria were excluded from all collections.
Genotyping and data analysis
Genotyping of genomic DNA samples was performed using the MassAR-RAY iPLEX TM assay (Sequenom, San Diego, CA, USA) for 13 SNPs, and a further two SNPs were genotyped using commercially available [9] A/C 1q41 MIA3 28 0.02182 0.009071 c rs2383206 a [10] A/G 9p21 None 49 0.4589 0.2898 rs10757274 [10] G/A 9p21 None 49 0.6197 0.3379 rs2943634 [9] A/C 2q36 None 34 0.5925 0.3094 rs6922269 [8, 9] A/G 6q25 MTHFD1L 29 0.4176 0.3462 rs383830 [8] T/A 5q21 None 21 0.04421 0.3529 rs501120 [9] G/A 10q11 None 14 0.4317 0.5454 rs688034 [8] T/C 22q12 SEZ6L 34 0.4492 0.4682 rs17672135 [8] C/T 1q43 FMN2 12 0.7447 0.6367 rs17228212 [9] C/T 15q22 SMAD3 30 0.6222 0.662 rs8055236 [8] T/G 16q24 CDH13 20 0.9462 0.7458 rs599839 a [9] G/A 1p13 PSRC1 22 0.9055 0.7927 rs1333049 [8, 9] C/G 9p21 None 47 0.5752 0.7858 rs7250581 [8] A/G 19q12 None 20 0.7754 0.9058 a SNPs genotyped by TaqMan.
Initially, the genotypic test (2df, -model -cell 5) was used to provide a general test of association for the single phenotype (case/control) of diabetic nephropathy. The basic allelic chi-square test (1df, -assoc) was used to provide asymptotic P-values. Adjustment for multiple testing was performed using Bonferroni's method.
TaqMan R kits (Applied Biosystems, Warrington, UK), as previously described [11] . Quality checks of genotyping data were performed, including individual and SNP-based call rates, departures from the Hardy-Weinberg equilibrium, duplicate error rates and Mendelian inconsistencies.
Statistical analysis
Analyses were performed using the standard tests implemented in PLINK [13] . Initially, the genotypic test (2df, -model -cell 5) was used to provide a general test of association for the single phenotype (case/control) of diabetic nephropathy. The basic allelic chi-square test (1df, -assoc) was used to provide asymptotic P-values and odds ratios (95% confidence interval) for minor alleles. The level of statistical significance was set at 5%, and the adjustment for multiple testing was performed using Bonferroni's method. Allele counts from both case-control collections were combined using a stratified analysis for Mantel-Haenszel odds ratio to minimize potential confounding between populations. Haplotype analysis was conducted where SNPs formed a haplotype block using 95% confidence bounds on D . The initial UK case-control collection had >80% power to identify an allele with an odds ratio of at least 1.5, assuming a minor allele frequency of 10% in controls.
Results
Prior to statistical analysis, nine individuals were removed from the UK case-control dataset where no genotypes were obtained for more than one SNP; remaining genotype completion rates were >99%. Minor allele frequencies exceeded 10% for all variants (Table 2 ) and the distributions of genotypes in cases and controls were consistent with the Hardy-Weinberg equilibrium. Experimental controls were as expected. Two SNPs demonstrated evidence for association with diabetic nephropathy in the UK case-control collection, but only one remained significant after Bonferroni correction for multiple testing; rs17465637 P genotype = 0.02; P allele = 0.009; P corrected = 0.2 and rs4420638 P genotype = 0.0004; P allele = 0.0002; P corrected = 0.002, OR = 1.5 (95% CI: 1.2-1.9).
Statistically significant evidence for association was also observed in a separate All Ireland population, providing convincing support for the involvement of this novel SNP in diabetic nephropathy (P = 0.002; Table 3 ). Combining these two collections by stratified analysis revealed an odds ratio of 1.54 (95% CI: 1.29-1.84; P < 0.00001). No significant distortion in transmission frequency was observed for rs4420638 in families (P = 0.3). Consistent with previous findings, strong LD (D > 0.95) was observed for three variants localized to chromosome 9p21 (rs10757274, rs2383206, rs1333049); frequencies of estimated haplotypes for these markers were similar in case and control groups (data not shown). The two most commonly observed haplotypes were AAG (47% versus 50%, P = 0.2) and GGC (46% versus 46%, P = 0.9) in cases and controls, respectively. 
Discussion
Utilizing a relatively large (n = 1099) collection of individuals with type 1 diabetes with or without nephropathy, we observed positive associations for two loci at the 5% level. One marker (rs4420638) remained statistically significant following stringent adjustment for multiple testing, and was replicated in a second case-control collection. The lack of statistically significant support in the family-based association study may be due to the small sample size, or explained by rs4420638 in linkage disequilibrium with the diseasecausing allele. Of note, we also found a non-significant increase of the minor allele in diabetic nephropathy patients, compared to non-nephropathic controls, with type 2 diabetes from Northern Ireland (n = 494; 17.9% versus 14.6%). It is possible that the significant association identified in this study is due to susceptibility to cardiovascular disease in patients with nephropathy rather than a shared mechanism contributing to both end points. A large, longterm prospective study, such as the FinnDiane cohort, may ultimately be able to test the interaction between CVD, diabetic nephropathy and genotypes. SNP rs17465637 (allele-based P uncorrected = 0.009) was also genotyped in the All Ireland population to further investigate the association of this marker with diabetic nephropathy. The resultant allele-based P = 0.7056 supports the theory that this SNP is not strongly associated with diabetic nephropathy in individuals with type 1 diabetes from the British Isles.
Genome-wide association studies [9] suggest strong LD within this region of 19q13; however, the genomic region is poorly mapped for genomic variation based on information in online resources. Indeed, APOC1/APOE loci are poorly tagged by the Affymetrix 500K chip [8] . The SNP statistically associated with diabetic nephropathy (rs4420638) is linked to APOC1, but the adjacent region contains three other APO genes (APOC2, APOC4, APOE) in close proximity ( Figure 1 ). APOC1 has been suggested to exacerbate dyslipidaemia [14] . Increased apoCIII has been reported in patients with chronic renal failure, and an increase in apoCI has been specifically observed with diabetic nephropathy [15] . Several studies have examined a limited number of genetic variants in APOC2, APOC4 and APOE genes for association with diabetic nephropathy [7] . It has been suggested that rs4420638 co-inherits with APOE genotypes [16] , which are ∼14 kb away. Both statistically significant association and a lack of association with nephropathy have been observed for genetic profiles at the APOE locus in individuals with diabetes [7] . Due to the lack of publicly available SNP data in this region, extensive resequencing is required to identify appropriate SNPs for genotyping. Fine mapping of the adjacent genomic region and replication by other groups will help to confirm this SNP as a genuine susceptibility allele or part of an important haplotype.
In conclusion, we have identified a previously unreported association of rs4420638 at 19q13 with diabetic nephropathy in two type 1 diabetic populations from the British Isles.
